Journal of Medicinal Chemistry · 2004 · 124 citations · 28 references
PharmacyChemistryMedicinal ChemistryDrug DesignDrug DiscoveryOrganic ChemistryAntiretroviral TherapyAntiviral AgentsAntiviral PharmacologyAntiviral TherapyEnzyme InhibitionHeterocyclic ChemistryAntiviral Drug DesignAntiviral Structure-activity RelationshipsCell-based AssaysIndole ChemistryIndole DerivativesIntegrase Strand Transfer InhibitorsMedicinal HeterocyclesSelectivity
Diketo acids such as S-1360 (1A) and L-731,988 (2) are potent and selective inhibitors of HIV-1 integrase (IN). A plethora of diketo acid-containing compounds have been claimed in patent literature without disclosing much biological activities and synthetic details (reviewed in Neamati, N. Exp. Opin. Ther. Pat. 2002, 12, 709-724). To establish a coherent structure-activity relationship among the substituted indole nucleus bearing a beta-diketo acid moiety, a series of substituted indole-beta-diketo acids (4a-f and 5a-e) were synthesized. All compounds tested showed anti-IN activity at low micromolar concentrations with varied selectivity against the strand transfer process. Three compounds, the indole-3-beta-diketo acids 5a and 5c, and the parent ester 9c, have shown an antiviral activity in cell-based assays. We further confirmed a keto-enolic structure in the 2,3-position of the diketo acid moiety of a representative compound (4c) using NMR and X-ray crystallographic analysis. Using this structure as a lead for all of our computational studies, we found that the title compounds extensively interact with the essential amino acids on the active site of IN.
28
O. S. Weislow, Rebecca Kiser, Donald L. Fine et al. · JNCI Journal of the National Cancer Institute · 1989 · 691 citations